Top Markets
#1 Bitway Bitway +55.99%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +39.20%
#3 Starpower Starpower +36.58%
#4 Pons Pons +34.90%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.72%
#6 aelf aelf +20.67%
#7 SkyAI SkyAI +19.93%
#8 Ocean Protocol Ocean Protocol +17.12%
#9 Mubarak Mubarak +16.27%
#10 Decred Decred +15.76%
Coin of the day
Bitway Bitway
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
SynCore Biotechnology Co.,Ltd SynCore Biotechnology Co.,Ltd

SynCore Biotechnology Co.,Ltd

4192
Classificação em ações #29318
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the... SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Preço da ação
$0.62008105
Última sincronização: 2026-08-18
Valor de mercado
$21.81M
Variação (1 dia)
0.26%
Variação (1 ano)
-31.95%
País
TW
Negociar SynCore Biotechnology Co.,Ltd (4192)

Categoria

Healthcare
Receita da SynCore Biotechnology Co.,Ltd (4192)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da SynCore Biotechnology Co.,Ltd, a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da SynCore Biotechnology Co.,Ltd de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH